市場調查報告書
商品編碼
1452553
南美洲和中美洲急性胰臟炎市場預測至 2030 年 - 區域分析 - 按產品、原因和最終用戶South & Central America Acute Pancreatitis Market Forecast to 2030 - Regional Analysis - by Offerings, Causes, and End User |
2022年,南美洲和中美洲急性胰臟炎市值為2.0904億美元,預計2030年將達到3.3367億美元;預計 2022 年至 2030 年CAGR為 6.0%。
急性胰臟炎研發活動和宣傳項目數量激增推動南美洲和中美洲急性胰臟炎市場
全球正在進行廣泛的研究,以調查急性胰臟炎的病因、進展和治療。國家胰臟基金會 (NPF) 提供多項研究資助,每個計畫價值約 5 萬美元。迄今為止,NPF 已為 133 個突破性研究項目提供了超過 500 萬美元的資金。授予為期一年的補助金,用於診斷和/或治療胰臟炎、胰臟癌或小兒胰臟炎。
此外,國際上正在進行一些努力來定義急性胰臟炎的流行病學和病理生理學。美國國立衛生研究院 (NIH) 的國家糖尿病、消化和腎臟疾病研究所 (NIDDK) 於 2020 年組建了一個由 10 個臨床中心和 1 個資料協調中心組成的協作網路,以解決有關急性胰臟炎的多個知識缺口。該聯盟被稱為急性胰臟炎聯盟 (T1DAPC) 後的第 1 型糖尿病。因此,針對急性胰臟炎開發有效療法(透過直接和間接手段)的研發活動和宣傳計畫預計將為南美洲和中美洲急性胰臟炎市場的公司帶來豐碩成果。
南美洲和中美洲急性胰臟炎市場概述
南美洲和中美洲急性胰臟炎市場分為巴西、阿根廷以及南美洲和中美洲其他地區。該地區老年人口的增加和急性胰臟炎病例的增加正在推動該地區南美洲和中美洲急性胰臟炎市場的成長。急性胰臟炎是一種危及生命的疾病,尤其是由於合併症和身體系統受損而導致的老年族群。據巴西衛生部稱,到 2030 年,巴西老年人口預計將在全球排名第五。世界衛生組織預計,2050年,我國老年人口將增加300%以上,總人口將成長30%。根據泛美衛生組織(PAHO)統計,2022年,巴西60歲以上人口將超過3,000萬,佔總人口的30%。預計到2050年,60歲以上的人口將達到約5,000萬,佔巴西總人口的24%。除了老化之外,飲酒也會導致急性胰臟炎。根據《自然》雜誌發表的一篇文章,巴西飲酒者總數的85.2%是重度飲酒者。因此,巴西酒精消費的增加也推動了南美洲和中美洲急性胰臟炎市場的成長。
南美洲及中美洲急性胰臟炎市場收入及 2030 年預測(百萬美元)
南美洲和中美洲急性胰臟炎市場細分
南美洲和中美洲急性胰臟炎市場按產品、原因、最終用戶和國家進行細分。
根據產品,南美洲和中美洲急性胰臟炎市場分為藥物、診斷等。 2022年,診斷細分市場佔據最大市場佔有率。
根據病因,南美洲和中美洲急性胰臟炎市場分為膽結石、酗酒、遺傳性疾病、感染等。 2022 年,膽結石細分市場佔據最大的市場佔有率。
根據最終用戶,南美洲和中美洲急性胰臟炎市場分為醫院、診斷實驗室、門診手術中心等。 2022 年,醫院細分市場佔據最大市場佔有率。
根據國家/地區,南美洲和中美洲急性胰臟炎市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,南美洲和中美洲其他地區主導了南美洲和中美洲急性胰臟炎市場佔有率。
Abbott Laboratories、Baxter International Inc、Boston Scientific Corp、Fresenius Kabi AG、GE HealthCare Technologies Inc、Koninklijke Philips NV、Medtronic Plc 和 Samsung Healthcare 是南美洲和中美洲急性胰臟炎市場的一些領先公司。
The South & Central America acute pancreatitis market was valued at US$ 209.04 million in 2022 and is expected to reach US$ 333.67 million by 2030; it is estimated to grow at a CAGR of 6.0% from 2022 to 2030.
Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis Fuels the South & Central America Acute Pancreatitis Market
Extensive research studies are being conducted globally to investigate the etiology, progress, and treatment of acute pancreatitis. The National Pancreas Foundation (NPF) provides multiple research grants worth ~US$ 50,000 per project. To date, the NPF has provided more than US$ 5 million for 133 ground-breaking research projects. A grant is awarded for a period of a year to diagnose and/or treat pancreatitis, pancreatic cancer, or pediatric pancreatitis.
Further, several ongoing international efforts are being made to define the epidemiology and pathophysiology of acute pancreatitis. The National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH), formed a collaborative network of 10 clinical centers and 1 data coordination center in 2020 to address several knowledge gaps regarding acute pancreatitis. The consortium is referred to as Type 1 Diabetes after Acute Pancreatitis Consortium (T1DAPC). Thus, R&D activities and awareness programs on acute pancreatitis for the development of effective therapies (through direct and indirect means) are expected to be highly fruitful for companies in the South & Central America acute pancreatitis market.
South & Central America Acute Pancreatitis Market Overview
The South & Central America acute pancreatitis market is segmented into Brazil, Argentina, and the Rest of South & Central America. Increasing in geriatric population in the region and increase in cases of acute pancreatitis is fueling the growth of the South & Central America acute pancreatitis market in the region. Acute pancreatitis is a life-threatening disease, especially in the geriatric population due to co-morbidities and compromised body systems. As per Brazil's Ministry of Health, by 2030, Brazil is anticipated to rank fifth in terms of geriatric population worldwide. The WHO estimated that the elderly population will have increased by more than 300% and the overall population will grow by 30% by 2050 in the country. According to Pan American Health Organization (PAHO), in 2022, Brazil had more than 30 million people aged above 60, which represents 30% of the total population. The number of people aged above 60 is expected to reach ~50 million, which is expected to represent 24% of the total population of Brazil by 2050. Apart from aging, alcohol consumption can also cause acute pancreatitis. According to an article published in Nature, 85.2% of the total alcohol drinkers were heavy drinkers in Brazil. Thus, the increase in alcohol consumption in Brazil is also fueling the growth of the South & Central America acute pancreatitis market.
South & Central America Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)
South & Central America Acute Pancreatitis Market Segmentation
The South & Central America acute pancreatitis market is segmented offerings, causes, end user, and country.
Based on offerings, the South & Central America acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.
Based on causes, the South & Central America acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.
Based on end user, the South & Central America acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America acute pancreatitis market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the South & Central America acute pancreatitis market share in 2022.
Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the South & Central America acute pancreatitis market.